drugset / Trial / NCT00050934

Pediatric Epilepsy Study

NCT00050934

Phase 3 Completed 132 enrolled Novartis Pharmaceuticals
Treatment

Summary

This study will evaluate the safety and effectiveness of oxcarbazepine (Trileptal) as add-on therapy in the treatment of partial seizures in pediatric patients 1 month to 3 years of age.

Timeline

Start
2002-06
Primary completion
2004-06
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxcarbazepine Small molecule

Indications